Biogen Q2 GAAP EPS $7.24, revenue $2.59B down 7% YoY; raises FY2022 guidance

BIOGEN INC.

2022-Q1 EPS reported $9.27 revenue$5,120,900,000

Revenue $2,589M (-7% YoY); GAAP EPS $7.24, Non-GAAP EPS $5.25.
MS revenue $1,719M (-4% YoY); SPINRAZA $431M (-14%); Biosimilars $194M.
FDA Priority Review for lecanemab in early Alzheimer's; decision by Jan 6, 2023; Phase 3 data expected Fall 2022.
Positive Phase 3 for zuranolone in PPD; joint US filing for MDD and PPD expected H2 2022.
Company raises full year 2022 financial guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.